Advertisement

Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C

Authors

  • John D. Ryan,

    Corresponding author
    1. Centre for Liver Disease, Mater Misericordiae University Hospital, Dublin, Ireland
    2. School of Medicine and Medical Science, University College Dublin, Ireland
    • Center for Liver Disease, Mater Misericordiae University Hospital, 55 Eccles Street, Dublin 7, Ireland
    Search for more papers by this author
    • fax: 0035318034058

  • Sandro Altamura,

    1. Department of Pediatric Hematology, Oncology and Immunology, University of Heidelberg, Heidelberg, Germany
    2. Molecular Medicine Partnership Unit, University of Heidelberg, Heidelberg, Germany
    Search for more papers by this author
  • Emma Devitt,

    1. Centre for Liver Disease, Mater Misericordiae University Hospital, Dublin, Ireland
    2. School of Medicine and Medical Science, University College Dublin, Ireland
    Search for more papers by this author
  • Sarah Mullins,

    1. Centre for Liver Disease, Mater Misericordiae University Hospital, Dublin, Ireland
    Search for more papers by this author
  • Matthew W. Lawless,

    1. Centre for Liver Disease, Mater Misericordiae University Hospital, Dublin, Ireland
    Search for more papers by this author
  • Martina U. Muckenthaler,

    1. Department of Pediatric Hematology, Oncology and Immunology, University of Heidelberg, Heidelberg, Germany
    2. Molecular Medicine Partnership Unit, University of Heidelberg, Heidelberg, Germany
    Search for more papers by this author
  • John Crowe

    1. Centre for Liver Disease, Mater Misericordiae University Hospital, Dublin, Ireland
    2. School of Medicine and Medical Science, University College Dublin, Ireland
    Search for more papers by this author

  • Potential conflict of interest: Nothing to report.

Abstract

Pegylated interferon-α (PEG-IFN-α) forms an integral part of the current treatment for hepatitis C virus (HCV) infection. PEG-IFN-α suppresses HCV production by augmenting the innate antiviral immune response. Recent studies have reported the induction of hepcidin, the iron regulatory hormone, by IFN-α in vitro. As hepcidin plays an important role in innate immunity, we hypothesized that this finding may be of clinical relevance to HCV and investigated the changes in iron homeostasis during the first 24 hours of treatment. Blood samples were obtained from HCV patients immediately prior to and 6, 12, and 24 hours following the first dose of PEG-IFN-α/ribavirin (RBV). Samples were analyzed for hepcidin, cytokine, iron levels, and HCV viral load, and hepcidin messenger RNA (mRNA) expression was quantified in peripheral blood mononuclear cells. Hepcidin induction by IFN-α was further analyzed in cell culture. In HCV patients a single dose of PEG-IFN-α/RBV resulted in a significant increase in serum hepcidin, peaking at 12 hours, coinciding with a 50% reduction in serum iron and transferrin saturation over the 24-hour period. Patients with a ≥2 log decline in HCV viral load over the first 24 hours had significantly lower SI and TS levels at 12 and 24 hours. Moreover, 24-hour SI levels were an independent predictor of the immediate HCV viral decline, an indicator of ultimate treatment outcome. In cell culture, a direct induction of hepcidin by IFN-α was seen, controlled by the STAT3 transcription factor. Conclusion: Hepcidin induction occurs following the initiation of PEG-IFN-α treatment for HCV, and is mediated by way of STAT3 signaling. The subsequent hypoferremia was greatest in those with the most significant decline in viral load, identifying systemic iron withdrawal as a marker of immediate interferon-α efficacy in HCV patients. (HEPATOLOGY 2012)

Ancillary